scholarly journals Polyacrylate-GnRH Peptide Conjugate as an Oral Contraceptive Vaccine Candidate

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1081
Author(s):  
Mohammad O. Faruck ◽  
Prashamsa Koirala ◽  
Jieru Yang ◽  
Michael J. D’Occhio ◽  
Mariusz Skwarczynski ◽  
...  
Keyword(s):  
Immune Responses ◽  
Oral Administration ◽  
Vaccine Candidate ◽  
Peptide Hormone ◽  
Swine Flu ◽  
T Helper ◽  
Contraceptive Vaccine ◽  
Polymer Conjugate ◽  
Flu Virus ◽  
Contraceptive Vaccines

Contraceptive vaccines are designed to elicit immune responses against major components of animal reproductive systems. These vaccines, which are most commonly administered via injection, typically target gonadotropin-releasing hormone (GnRH). However, the need to restrain animals for treatment limits the field applications of injectable vaccines. Oral administration would broaden vaccine applicability. We explored contraceptive vaccine candidates composed of GnRH peptide hormone, universal T helper PADRE (P), and a poly(methylacrylate) (PMA)-based delivery system. When self-assembled into nanoparticles, PMA-P-GnRH induced the production of high IgG titers after subcutaneous and oral administration in mice. PADRE was then replaced with pig T helper derived from the swine flu virus, and the vaccine was tested in pigs. High levels of systemic antibodies were produced in pigs after both injection and oral administration of the vaccine. In conclusion, we developed a simple peptide–polymer conjugate that shows promise as an effective, adjuvant-free, oral GnRH-based contraceptive vaccine.

scholarly journals Evaluation of Early Innate and Adaptive Immune Responses to the TB Vaccine Mycobacterium Bovis BCG and Vaccine Candidate BCGdBCG1419c

2021 ◽  
Author(s):  
Manuja Gunasena ◽  
Rajni Kant Shukla ◽  
Naiquan Yao ◽  
Oscar Rosas Mejia ◽  
Michael D Powell ◽  
...  
Keyword(s):  
Immune Responses ◽  
Mycobacterium Bovis ◽  
Biofilm Formation ◽  
Vaccine Candidate ◽  
Flow Cytometric Analysis ◽  
Lung Pathology ◽  
T Helper ◽  
Vaccine Candidates ◽  
Adaptive Immune ◽  
Flow Cytometric

Abstract The vaccine Mycobacterium bovis Bacillus Calmette–Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the BCG deletion mutant and vaccine candidate BCGDBCG1419c was demonstrated to survive longer in intravenously infected BALB/c mice due to enhanced biofilm formation, and better protected both BALB/c and C57BL/6 mice against TB-induced lung pathology during chronic stages of infection, relative to BCG controls. BCGDBCG1419c-elicited protection also associated with lower levels of proinflammatory cytokines (i.e. IL6, TNFa) at the site of infection in C57BL/6 mice. Given the distinct immune profiles of BCG- and BCGDBCG1419c-immunized mice during chronic TB, we set out to determine if there are early immunological events which distinguish these two groups, using multi-dimensional flow cytometric analysis of the lungs and other tissues soon after immunization. Our results demonstrate a number of innate and adaptive response differences between BCG- and BCGDBCG1419c-immunized mice which are consistent with the latter being longer lasting and potentially less inflammatory, including lower frequencies of exhausted CD4+ T helper (TH) cells and higher frequencies of IL10-producing T cells, respectively. These studies suggest the use of BCGDBCG1419c may be advantageous as an alternative TB vaccine candidate.

scholarly journals Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

2021 ◽  
Author(s):  
Peter G. Kremsner ◽  
Philipp Mann ◽  
Arne Kroidl ◽  
Isabel Leroux-Roels ◽  
Christoph Schindler ◽  
...  
Keyword(s):  
Immune Responses ◽  
Vaccine Candidate ◽  
Phase 1 ◽  
Lipid Nanoparticles ◽  
Enzyme Linked Immunosorbent Assay ◽  
Receptor Binding Domain ◽  
Igg Antibodies ◽  
Phase 1 Study ◽  
S Protein ◽  
Dosage Escalation

Summary Background We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP). Methods This is an interim analysis of a dosage escalation phase 1 study in healthy 18–60-year-old volunteers in Hannover, Munich and Tübingen, Germany, and Ghent, Belgium. After giving 2 intramuscular doses of CVnCoV or placebo 28 days apart we assessed solicited local and systemic adverse events (AE) for 7 days and unsolicited AEs for 28 days after each vaccination. Immunogenicity was measured as enzyme-linked immunosorbent assay (ELISA) IgG antibodies to SARS-CoV‑2 S‑protein and receptor binding domain (RBD), and SARS-CoV‑2 neutralizing titers (MN50). Results In 245 volunteers who received 2 CVnCoV vaccinations (2 μg, n = 47, 4 μg, n = 48, 6 μg, n = 46, 8 μg, n = 44, 12 μg, n = 28) or placebo (n = 32) there were no vaccine-related serious AEs. Dosage-dependent increases in frequency and severity of solicited systemic AEs, and to a lesser extent local AEs, were mainly mild or moderate and transient in duration. Dosage-dependent increases in IgG antibodies to S‑protein and RBD and MN50 were evident in all groups 2 weeks after the second dose when 100% (23/23) seroconverted to S‑protein or RBD, and 83% (19/23) seroconverted for MN50 in the 12 μg group. Responses to 12 μg were comparable to those observed in convalescent sera from known COVID-19 patients. Conclusion In this study 2 CVnCoV doses were safe, with acceptable reactogenicity and 12 μg dosages elicited levels of immune responses that overlapped those observed in convalescent sera.

scholarly journals Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines

2021 ◽  
Vol 9 (4) ◽  
pp. 683
Author(s):  
Julio Villena ◽  
Chang Li ◽  
Maria Guadalupe Vizoso-Pinto ◽  
Jacinto Sacur ◽  
Linzhu Ren ◽  
...  
Keyword(s):  
Immune Responses ◽  
Oral Administration ◽  
Molecular Mechanisms ◽  
Spike Protein ◽  
Heterologous Proteins ◽  
Oral Vaccines ◽  
Adaptive Immune Responses ◽  
Adaptive Immune ◽  
Viral Antigens ◽  
Mucosal Infection

The most important characteristics regarding the mucosal infection and immune responses against the Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as well as the current vaccines against coronavirus disease 2019 (COVID-19) in development or use are revised to emphasize the opportunity for lactic acid bacteria (LAB)-based vaccines to offer a valid alternative in the fight against this disease. In addition, this article revises the knowledge on: (a) the cellular and molecular mechanisms involved in the improvement of mucosal antiviral defenses by beneficial Lactiplantibacillus plantarum strains, (b) the systems for the expression of heterologous proteins in L. plantarum and (c) the successful expressions of viral antigens in L. plantarum that were capable of inducing protective immune responses in the gut and the respiratory tract after their oral administration. The ability of L. plantarum to express viral antigens, including the spike protein of SARS-CoV-2 and its capacity to differentially modulate the innate and adaptive immune responses in both the intestinal and respiratory mucosa after its oral administration, indicates the potential of this LAB to be used in the development of a mucosal COVID-19 vaccine.

scholarly journals Distribution and Immune Responses Resulting from Oral Administration of D-Limonene in Rats.

2002 ◽  
Vol 48 (2) ◽  
pp. 155-160 ◽  
Author(s):  
Masafumi HAMADA ◽  
Kayoko UEZU ◽  
Junko MATSUSHITA ◽  
Shigeru YAMAMOTO ◽  
Yasuo KISHINO
Keyword(s):  
Immune Responses ◽  
Oral Administration
Sign in / Sign up

Export Citation Format

Share Document